Rachael Lawrance
0000-0002-9499-8443
Publication & Citation Trends
Most Cited Works
Publications
47 total
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial PDF
Cited by 17
OpenAlex
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes PDF
Cited by 17
OpenAlex
Reflections on estimands for patient-reported outcomes in cancer clinical trials PDF
Cited by 9
OpenAlex
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743 PDF
Cited by 34
OpenAlex
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
Cited by 18
OpenAlex
What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials? PDF
Cited by 65
OpenAlex
What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD
Cited by 20
OpenAlex
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial PDF
Cited by 215
OpenAlex
Research Topics
Health Systems, Economic Evaluations, Quality of Life
(15)
Cancer Immunotherapy and Biomarkers
(8)
Lung Cancer Treatments and Mutations
(8)
Economic and Financial Impacts of Cancer
(8)
Asthma and respiratory diseases
(6)
Frequent Co-Authors
Affiliations
AstraZeneca (United Kingdom)
Adelphi Group (United Kingdom)
AstraZeneca (Singapore)
The Task Force for Global Health
AstraZeneca (United States)